FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093403276> ?p ?o ?g. }

• W2093403276 endingPage "385" @default.
• W2093403276 startingPage "376" @default.
• W2093403276 abstract "Objectives The aims of this multicenter, randomized, placebo-controlled, double-blind trial were to confirm the efficacy of lacosamide at a daily dose of 400 mg/d and to explore the efficacy, safety, and tolerability of lacosamide 200 mg/d and 600 mg/d in the treatment of painful diabetic neuropathy. Methods The trial consisted of a 2-week run-in period, a 6-week titration phase, and a 12-week maintenance phase, during which patients received placebo or fixed doses of lacosamide 200, 400, or 600 mg/d. No back titration was allowed during the trial. The primary efficacy criterion was the change in Likert pain score from baseline to the average over the last 4 weeks of the maintenance phase in the intent-to-treat population. Results The lacosamide 400 mg/d group demonstrated statistically significant improvement in Likert pain score over placebo for the primary efficacy measure. At the end of treatment, 58% of patients in the lacosamide 400 mg/d treatment group achieved at least a 2-point or 30% reduction in Likert pain score, compared with 46% of placebo-treated patients. The lacosamide 200 mg/d group separated from placebo, but failed to show statistical significance for any of the primary or secondary outcome measures. The lacosamide 600 mg/d group was significantly more efficacious than placebo in the observed cases but not in the intent-to-treat population. This was probably secondary to a relatively high-premature withdrawal rate due to adverse events that occurred during the titration phase in that group. Overall lacosamide at daily doses of 200 to 400 mg was well tolerated, with 8% of patients discontinuing due to an adverse event from the 200 mg/d group and 23% from the 400 mg/d group compared with 9% in the placebo group. Discontinuations due to adverse events were highest in the 600 mg/d group (40%). The most common adverse events consisted of dizziness, nausea, tremor, headache, and fatigue. Somnolence, cognitive and behavioral side effects, weight change, and edema were notably low. Discussion Safety and efficacy analyses indicated that lacosamide 400 mg/d provided an optimal balance between efficacy and side effects in patients with painful diabetic neuropathy." @default.
• W2093403276 created "2016-06-24" @default.
• W2093403276 creator A5007630303 @default.
• W2093403276 creator A5041333516 @default.
• W2093403276 creator A5067078047 @default.
• W2093403276 creator A5080276406 @default.
• W2093403276 date "2009-06-01" @default.
• W2093403276 modified "2023-10-17" @default.
• W2093403276 title "Efficacy and Safety of Lacosamide in Diabetic Neuropathic Pain" @default.
• W2093403276 cites W1581758663 @default.
• W2093403276 cites W1969434736 @default.
• W2093403276 cites W1970276411 @default.
• W2093403276 cites W1972387365 @default.
• W2093403276 cites W1977292812 @default.
• W2093403276 cites W1978336088 @default.
• W2093403276 cites W1983215991 @default.
• W2093403276 cites W1984353492 @default.
• W2093403276 cites W1989781105 @default.
• W2093403276 cites W1990660816 @default.
• W2093403276 cites W1998125049 @default.
• W2093403276 cites W2012730087 @default.
• W2093403276 cites W2014670473 @default.
• W2093403276 cites W2025797846 @default.
• W2093403276 cites W2036785454 @default.
• W2093403276 cites W2037208185 @default.
• W2093403276 cites W2038764202 @default.
• W2093403276 cites W2042071004 @default.
• W2093403276 cites W2043285983 @default.
• W2093403276 cites W2043595892 @default.
• W2093403276 cites W2048279142 @default.
• W2093403276 cites W2053511468 @default.
• W2093403276 cites W2054260401 @default.
• W2093403276 cites W2057621238 @default.
• W2093403276 cites W2068602147 @default.
• W2093403276 cites W2075769621 @default.
• W2093403276 cites W2079286087 @default.
• W2093403276 cites W2092800391 @default.
• W2093403276 cites W2106059433 @default.
• W2093403276 cites W2112438385 @default.
• W2093403276 cites W2127941203 @default.
• W2093403276 cites W2129860136 @default.
• W2093403276 cites W2132309748 @default.
• W2093403276 cites W2142796780 @default.
• W2093403276 cites W2153789216 @default.
• W2093403276 cites W2153884620 @default.
• W2093403276 cites W2159977024 @default.
• W2093403276 cites W2329242769 @default.
• W2093403276 cites W2406919090 @default.
• W2093403276 cites W3022230988 @default.
• W2093403276 cites W3187653885 @default.
• W2093403276 cites W59993581 @default.
• W2093403276 doi "https://doi.org/10.1097/ajp.0b013e318196d2b6" @default.
• W2093403276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19454870" @default.
• W2093403276 hasPublicationYear "2009" @default.
• W2093403276 type Work @default.
• W2093403276 sameAs 2093403276 @default.
• W2093403276 citedByCount "123" @default.
• W2093403276 countsByYear W20934032762012 @default.
• W2093403276 countsByYear W20934032762013 @default.
• W2093403276 countsByYear W20934032762014 @default.
• W2093403276 countsByYear W20934032762015 @default.
• W2093403276 countsByYear W20934032762016 @default.
• W2093403276 countsByYear W20934032762017 @default.
• W2093403276 countsByYear W20934032762018 @default.
• W2093403276 countsByYear W20934032762019 @default.
• W2093403276 countsByYear W20934032762020 @default.
• W2093403276 countsByYear W20934032762021 @default.
• W2093403276 countsByYear W20934032762022 @default.
• W2093403276 countsByYear W20934032762023 @default.
• W2093403276 crossrefType "journal-article" @default.
• W2093403276 hasAuthorship W2093403276A5007630303 @default.
• W2093403276 hasAuthorship W2093403276A5041333516 @default.
• W2093403276 hasAuthorship W2093403276A5067078047 @default.
• W2093403276 hasAuthorship W2093403276A5080276406 @default.
• W2093403276 hasConcept C118552586 @default.
• W2093403276 hasConcept C126322002 @default.
• W2093403276 hasConcept C142724271 @default.
• W2093403276 hasConcept C168563851 @default.
• W2093403276 hasConcept C197934379 @default.
• W2093403276 hasConcept C203092338 @default.
• W2093403276 hasConcept C204787440 @default.
• W2093403276 hasConcept C27081682 @default.
• W2093403276 hasConcept C2778139780 @default.
• W2093403276 hasConcept C2778186239 @default.
• W2093403276 hasConcept C2778375690 @default.
• W2093403276 hasConcept C2908647359 @default.
• W2093403276 hasConcept C42219234 @default.
• W2093403276 hasConcept C71924100 @default.
• W2093403276 hasConcept C99454951 @default.
• W2093403276 hasConceptScore W2093403276C118552586 @default.
• W2093403276 hasConceptScore W2093403276C126322002 @default.
• W2093403276 hasConceptScore W2093403276C142724271 @default.
• W2093403276 hasConceptScore W2093403276C168563851 @default.
• W2093403276 hasConceptScore W2093403276C197934379 @default.
• W2093403276 hasConceptScore W2093403276C203092338 @default.
• W2093403276 hasConceptScore W2093403276C204787440 @default.
• W2093403276 hasConceptScore W2093403276C27081682 @default.
• W2093403276 hasConceptScore W2093403276C2778139780 @default.

• next